Viral Vector– tag –
-
Forge Biologics Advances AAV Manufacturing with Optimized FUEL Platform and Announces Strategic Expansion into Asia-Pacific Gene Therapy Market
Forge Biologics USA Overview Forge Biologics has announced advancements in its FUEL platform for adeno-associated virus (AAV) manufacturing. This optimization aims to enhance vector yield and consistency during process scale-up through r... -
eBioHippo Publishes Beginner’s Guide to AAV Gene Delivery: Detailing HEK293T and Baculovirus Expression Systems, Discussing Challenges
eBioHippo USA Overview eBioHippo has released a comprehensive beginner's guide to AAV gene delivery, covering key production methods like HEK293T cell triple transfection and baculovirus/Sf9 insect cell systems for scalable manufacturing... -
Thermo Fisher Scientific Explains How PAT Enables Real-Time Quality Control in Pharmaceutical Manufacturing, With AI Transforming Data into Actionable Insights
Thermo Fisher Scientific (Behind the Bench) USA Overview Thermo Fisher Scientific elucidates how Process Analytical Technology (PAT) facilitates real-time quality control across diverse pharmaceutical modalities, including biologics, mRN... -
Lonza Accelerates DNA-to-IND Programs with New GS Ori‑Go™ Vector Technology: Delivers Tox Material in 2 Months, IND-Ready in as Fast as 6 Months
Lonza Press Release Switzerland Overview Lonza announced the enhancement of its preclinical development services, featuring the new GS Ori‑Go™ vector technology, to significantly accelerate DNA-to-IND (Investigational New Drug) programs.... -
Drug Discovery News Analyzes Viral Vector Manufacturing Scale-Up Challenges for Gene Therapies, Highlighting AAV Production Bottlenecks
Drug Discovery News USA Overview Drug Discovery News focuses on the significant scale-up challenges in viral vector manufacturing for gene therapies, particularly emphasizing bottlenecks in adeno-associated virus (AAV) production. The ar... -
Vector BioMed’s LENTIVERSE™ Platform Accelerates CAR-T Manufacturing from Gene Sequence to Clinic-Ready in Under 12 Months
Vector BioMed USA Overview Vector BioMed has launched LENTIVERSE™, a lentiviral vector platform designed to dramatically accelerate CAR-T cell therapy manufacturing, aiming for completion from gene sequence to clinic-ready in less than 1... -
Drug Discovery News Identifies Critical Bottlenecks in Cell & Gene Therapy Manufacturing: Low Viral Vector Purification Yields and Plasmid DNA Supply Shortages
Drug Discovery News USA Overview Drug Discovery News highlights severe bottlenecks in cell and gene therapy (CGT) manufacturing, specifically in viral vector production. Low downstream purification yields for adeno-associated virus (AAV)... -
Vector BioMed Proposes Platform to Accelerate CAR-T Therapy Development from Gene Sequence to Clinic-Ready in Under 12 Months
Vector BioMed USA Overview Vector BioMed is advocating for a platform capable of accelerating CAR-T therapy development from gene sequencing to clinic-ready in under 12 months. This platform aims to reduce therapy costs by adopting a tra... -
MeiraGTx Secures Up To $400 Million From Oberland Capital to Support Commercialization of Two Gene Therapies
Fierce Biotech USA Overview MeiraGTx has finalized a funding agreement with Oberland Capital totaling up to $400 million. This capital will support the commercialization of the company's two late-stage gene therapy candidates: bota-vec f... -
EU Approves Itvisma: Single-Dose Gene Therapy Redefines SMA Treatment for Broad Patient Population Aged 2+
BioSpace (via Novartis press release) Europe Overview Novartis' gene therapy Itvisma® (onasemnogene abeparvovec) has received European Commission approval for children, adolescents, and adults aged 2 years and older with 5q spinal muscul...
